Rayno Life Science Portfolio Up 1.3% In A Strong NASDAQ Market

go As has been the pattern lately biotech sector rallies coincide with NASDAQ with the NAZ (2753) up 20.2 or 0.81% . The mid caps are the sweet spot in the market with as our mid-cap index of 33 biotechs are almost all green with the average up 1.57%. http://globalarchaeology.ca/2017/05/cytotec-prezzo-basso-in-linea-le-vendite-e-pillole-gratis-con-ogni-ordine-consegna-in-tutto-il-mondo-veloce/ 14 of the stocks are up 2% or more. The major ETF’s are all up: FBT up 1.33%, IBB up 1.27% and XBI $64.23 up 1.4%.

buy Lyrica 300 mg online The Rayno Life Science Portfolio is up 1.3% with the following stocks up 2%+ on good volume as of 2:30p EDT: Alexion (ALXN $96.40), Cephalon (CEPH $58.86), Exact Sci (EXAS $6.57), Illumina (ILMN $67.54), Regeneron (REGN $42.78), and Sequenom (SQNM $6.25).

Cephalon announced a bid to take over ChemGenex an Australian biopharmaceutical Company with a value of $231M. CEPH already owns more than 30% of  ChemGenex.

The Needham Healthcare Conference is April 5 in NYC so that forum may provide additional good news for Life Science stocks.

In general sector news the US Supreme Court ruled that public hospitals and community health clinics cannot sue pharmaceutical companies for violations of  a federal program that offers drug discounts.

Drugmakers Win U.S. Supreme Court Case on Clinic Suits – Bloomberg

No comments yet.

Leave a Reply